Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST1: Neo-Adjuvant Atorvastatin in Breast Cancer
NCT00816244Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- Jan 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atorvastatin in breast cancer, sponsored by Skåne University Hospital. Primary endpoint: Tumor biological alterations (Ki67 proliferation marker) at 2 weeks. Started Jan 2009; status: completed.
02
Drugs
atorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00816244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816244.